Menu Close
Close
Make an Appointment

Expertise

Chemotherapy

Personalized chemotherapy treatment plans using the latest protocols and supportive care strategies to maximize effectiveness while minimizing side effects for patients with various cancers.

Cellular Therapies

Advanced cellular treatment options including CAR T-cell therapy and other innovative approaches that harness the body’s own cells to target and eliminate cancer.

Immunotherapies

Cutting-edge immunotherapy treatments that activate the immune system to recognize and attack cancer cells, offering new hope for patients with difficult-to-treat malignancies.

Hemato-oncology Consultation

Comprehensive evaluation and management of blood cancers including leukemia, lymphoma, and multiple myeloma, with expert guidance on diagnosis, treatment options, and long-term care planning.

Bone Marrow Aspiration and Biopsy

Skilled performance of diagnostic bone marrow procedures with attention to patient comfort, providing critical information for accurate diagnosis and treatment monitoring of hematologic conditions.

Other Diseases: Anemia, Malignant and Benign

Expert diagnosis and treatment of various blood disorders including iron-deficiency anemia, hemolytic conditions, and other benign hematologic diseases requiring specialized care.

Public Health & Outreach

Active involvement in cancer awareness initiatives, public health programs, and community screening camps focused on early detection, prevention, and improving access to quality hemato-oncology care.

Medical Training & Mentorship

Over 15 years of experience in teaching and mentoring postgraduate students, DNB trainees, and nursing professionals, with faculty roles in national CMEs, workshops, and hematology conferences.

Clinical Trials & Research

Principal Investigator and Co-Investigator in multiple national and international Phase II/III clinical trials, contributing to protocol development and advancement of evidence-based hemato-oncology treatment.

 
  • Priyanka Jujuvarapu, Shilpa Gupta, Vijay Dalal. Primary extranodal classical Hodgkin lymphoma presenting as a chest wall mass mimicking tuberculosis: A rare case report with long-term Follow-up
  • Gupta S. Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series. Leukemia & Lymphoma, 2012.
  • Book Chapter: Gastrointestinal Lymphomas in Recent Advances in Surgery – 2012, Jaypee
  • Principal Investigator / Co-Investigator in multiple trials, including:
  • 2024 | Phase III | Observational study on anticoagulant prescribing patterns – Principal Investigator.
  • 2023 | Phase III | PZN-128 in Chronic ITP – Principal Investigator.
  • Earlier experience: Multiple Phase III trials in colorectal cancer, breast cancer, T-cell lymphoma, ovarian cancer, and pancreatic cancer (2015–2017).
  • Dr. Shilpa Gupta, PI, A multicenter, randomised, open-label, three-parallel groups, phase 2-study to evaluate the efficacy and safety of masitinib with dexamethasone,gemcitabine with dexamethasone and the combination of masitinib,gemcitabine and dexamethasone in patients with relapsed or refractoryperipheral T-cell lymphoma, Trials, 27-Jun-16, NA, National, PhaseII/III, Completed.
  • Dr. Shilpa Gupta, Co-I, A multicenter, open label, randomized, balanced, two treatment, two period, two sequence, two way crossover, single dose, bioequivalence study of Doxorubicin Hydrochloride Liposome Injection (20mg/10mL) of Mylan Laboratories Limited, India with Doxorubicin Hydrochloride Liposome Injection for intravenous infusion 20 mg/10 mL. Manufactured By: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India, administered in female patients with ovarian cancer whose disease has progressed or recurred after platinum based chemotherapy under fed condition., Trials, 19-Jun-17, NA, National, BA-BE Study, Completed.
  • Dr. Shilpa Gupta, Co-I, A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib, and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM), Trials, 11-Jun-18, NA, International, III, Completed.
  • Dr. Shilpa Gupta, Co-I, Randomized, Assessor-Blind, Multicentre, Parallel Group, Two Arms, Clinical Study to Assess the Efficacy, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety of Rituximab (Test Product, Zydus) in comparison with Rituximab (Reference Product, Roche/Genentech) in Patients with Diffuse Large B Cell Lymphoma (DLBCL)”. (Trial No. RITU.17.001)., Trials, 8-Sep-18, NA, National, BA-BE Study, Completed.
  • Dr. Shilpa Gupta, Co-I, A Prospective, Randomized, Multicenter, Comparative, Open-label, Parallel study to evaluate the Efficacy, Safety and Pharmacokinetics of Test-TrastuzumabEmtansine (ZRC3256;Cadila Healthcare Ltd) and Reference-TrastuzumabEmtansine(Kadcyla; Roche Products (India) Pvt. Ltd.) in HER2- Positive Metastatic Breast Cancer Patients”. (Trial No. TDM11.17.001)., Trials, 8- Sep-18, NA, National, BA-BE Study, Completed.
  • Dr. Shilpa Gupta, PI, A randomized, international, multicenter single-blind study to compare the efficacy and safety of PZN-128 powder for solution for subcutaneous injection 250 μg (PharmasyntezNord JSC, Russia) versus comparator drug in patients with chronic idiopathic (immune) thrombocytopenic purpura, Trials, 19-Dec-23, REF/2023/09/03786, International, III, Completed.
  • Dr. Shilpa Gupta, PI, A single center, prospective, observational study to evaluate the factorsinfluencing the prescription choices of anticoagulants and to assess the outcomes in patients prescribed these specific anticoagulants., Investigator Initiated, 17-Sep-24, CTRI/2024/10/074833, Hospital Based, NA, Completed.